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Objectives
We investigated the effects on fracture healing of two up-regulators of inducible nitric oxide
synthase (iNOS) in a rat model of an open femoral osteotomy: tadalafil, a phosphodiesterase
inhibitor, and the recently reported nutraceutical, COMB-4 (consisting of L-citrulline, Paullinia
cupana, ginger and muira puama), given orally for either 14 or 42 days.

Materials and Methods
Unilateral femoral osteotomies were created in 58 male rats and fixed with an intra
medullary compression nail. Rats were treated daily either with vehicle, tadalafil or COMB-4.
Biomechanical testing of the healed fracture was performed on day 42. The volume, mineral content and bone density of the callus were measured by quantitative CT on days 14
and 42. Expression of iNOS was measured by immunohistochemistry.

Results
When compared with the control group, the COMB-4 group exhibited 46% higher maximum
strength (t-test, p = 0.029) and 92% higher stiffness (t-test, p = 0.023), but no significant
changes were observed in the tadalafil group. At days 14 and 42, there was no significant
difference between the three groups with respect to callus volume, mineral content and
bone density. Expression of iNOS at day 14 was significantly higher in the COMB-4 group
which, as expected, had returned to baseline levels at day 42.

Conclusion
This study demonstrates an enhancement in fracture healing by an oral natural product
known to augment iNOS expression.
Cite this article: Bone Joint Res 2017:6:90–97.
Keywords: Inducible nitric oxide synthase, Tadalafil, Fracture, Nutraceutical, Biomechanical

Article focus

 The stimulation of inducible nitric oxide synthase (iNOS) immediately post-osteotomy.
 The comparison of tadalafil and a nutraceutical in fracture healing.

Key messages

 The upregulation of iNOS may enhance
fracture healing as evidenced by biomechanical properties.
 The use of nutraceuticals that upregulate
iNOS may be considered as a supplement
to early fracture healing.

Strengths and limitations

 The randomised design with comparative
control group.
 The no dose response with either treatment arm.
 It was a small animal fracture model.
 The osteotomy created in metaphysealdiaphyseal junction.

Introduction

Fracture healing results from a complex and
sequential cascade of cellular events that
restore bone to its pre-fracture condition. The

90

91

Enhancement of fracture healing in the rat, modulated by compounds that stimulate inducible nitric oxide synthase

fracture site fills with a haematoma that is rich in mesenchymal cells and cytokines. This represents the inflammatory phase, and it is eventually followed by a reparative
phase in which soft callus is laid down, followed by a
remodeling phase.1 Although the exact regulatory mechanisms for these phases are yet to be fully understood, neovascularity, as well as osteoblast recruitment at the callus
site, appears to play a key role for successful healing.2,3
Neovascularity and osteoblastic recruitment are
known effects of nitric oxide (NO), which appears to be
involved in the fracture healing process.4,5 NO is produced by one of three isoforms of nitric oxide synthase
(NOS) depending on tissue location and physiological
function.6,7 While all three of these NOS isoforms are
involved in the fracture healing process,8-10 inducible
NOS (iNOS) appears to be the primary isoform involved
in the stimulation of osteoblasts by NO.11,12 Furthermore,
when the iNOS gene is selectively deleted, fracture healing is impaired. This can be reversed by treatment with
the iNOS gene.13
The effects of NO are normally mediated via its
second messenger, cyclic guanosine monophosphate
(cGMP),14,15 which is regulated by intracellular phosphodiesterase (PDE).16 Inhibitors of PDE, such as tadalafil, are
known to increase intracellular cGMP and have been
shown to accelerate early fracture healing in mice.17,18
Recently, Ferrini et al19 reported that a combination of the
four herbal compounds, L-citrulline, ginger, Paullinia
cupana, and muira puama (COMB-4), originally conceived as an anti-fibrotic compound, appeared in an in
vivo study to produce a marked stimulation of the iNOS
enzyme in rats.
We hypothesise that COMB-4 is capable of stimulating
iNOS to produce elevated levels of NO and, therefore,
will accelerate fracture healing, as has been shown with
PDE5 inhibition.17,18 Rodents have been increasingly used
to study fracture healing due to their ease of handling
and cost. Although there is no standard model for studying fracture healing in a rat, there are various fixation
techniques and fracture models described in the literature.20 By creating a reproducible osteotomy of the femur
and using an intramedullary (IM) nail that controlled
both axial and rotational stability, we created a unique
standardised experimental fracture healing model for a
rat from which to study the effects of both tadalafil and
COMB-4. The primary outcomes included the biomechanical parameters of torsional strength, stiffness, and
fracture healing stages. Secondary outcomes were bone
mineral density, callus volume, and iNOS expression at
the fracture site.

Materials and Methods

Experimental animals and surgical procedure. A total of

58 male Sprague-Dawley rats (ten weeks old, average body
weight: 344 g) were obtained from Harlan Labs/Envigo
(Indianapolis, Indiana). The protocol #1-1403-279 was

approved by the Charles R. Drew University Institutional
Animal Care and Use Committee. Male rats were used in
order to avoid the effects of the oestrous cycle (oestrogen)
as a variable. The rats were housed for one week prior
to experimental procedures to permit acclimatisation,
and then randomly assigned to three groups. The control group (n = 19) received 0.2 ml of vehicle composed
of 10% dimethyl sulfoxide, peanut butter and water by
retrolingual administration. The tadalafil group (n = 20)
received 2.0 mg/kg body weight (BW) of the PDE5 inhibitor, tadalafil (Eli Lilly, Indianapolis, Indiana), mixed with
the vehicle. This dose has been shown to be equivalent to
a 20 mg/day daily dose in humans.21 The COMB-4 group
(n = 19) received a combination of the following: muira
puama (45 mg/kg BW), Paullinia cupana (45 mg/kg BW),
and ginger (45 mg/kg BW) which were obtained from
Naturex (Hackensack, New Jersey) as well as L-citrulline
(133 mg/kg BW) which was obtained from Sigma Aldrich
(St Louis, Missouri). All four components were dissolved
in the vehicle. The appropriate dose of each of the four
components of COMB-4 for a rat was calculated based
on the equivalent recommended human daily dose as
previously reported.19 All animals received the vehicle
once a day for the three days prior to surgery to adapt to
the taste, and began receiving on a daily basis either their
respectively assigned control, or tadalafil or COMB-4
post osteotomy (day 0), which was continued until the
rats were killed at two or four weeks. All surgeries were
performed by one of the authors (AK) who was blinded
to the rats’ experimental assignment. Anaesthesia was
induced with 3% isoflurane and maintained with 2.5%
isoflurane throughout the surgery. All rats received subcutaneous injections of buprenorphine 0.05 mg/kg BW
for pre- and post-operative pain control.
Each rat then underwent a unilateral femoral osteotomy with internal fixation. Briefly, after shaving the skin,
the rat was placed in the supine position and a longitudinal incision 1.5 cm long-centred over the superior patella
was made just medial to the midline. The underlying fascia was incised at the medial patellar tendon border and
the patella was dislocated laterally. The trochlea was
opened with a 1.0 mm drill bit and the IM canal and
greater trochanter were reamed with a 21-gauge hypodermic needle. The canal was sequentially reamed with
an 18-gauge needle, and the epicondyle was further
opened with a 16-gauge needle. The femoral shaft was
accessed by sweeping the vastus medialis laterally. Cat
claw scissors (Petco, San Diego, California) placed at the
distal one-third of the femoral shaft were used to make a
transverse osteotomy. A randomiser table was used to
determine laterality of the osteotomy. While maintaining
control of both osteotomy fragments, a titanium compression IM nail (RISystem, Davos, Switzerland) was
applied in a retrograde manner, while visualising the
fracture reduction (Fig. 1). The use of this type of IM
device in rodents has been previously described.17,18
BONE & JOINT RESEARCH
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Fig. 1
Representative radiograph of a femur fixed with the intramedullary (IM) nail.
The proximal end of the IM nail has a thread that permits compression of the
femur fragments. This radiograph was taken after harvest at day 14.

A small amount of compression was seen at the osteotomy site indicating the IM nail obtained fixation proximally at the greater trochanter and the site was tested
manually for any movement.
The fascia and skin were closed in two layers using 4-0
Vicryl (Ethicon Inc., Somerville, New Jersey) and VetBond
skin glue (3M, St. Paul, Minnesota). A small amount of
triple antibiotic ointment (Actavis, Parsippany, New
Jersey) was applied to the skin. Range of movement at
the hip and knee was performed to ensure there was no
penetration of the IM nail proximally and that the patella
tracked appropriately. Unprotected weight-bearing was
permitted immediately post-operatively, and on day 14,
five rats from each of the three groups were killed using
inhalational CO2 and the femurs were harvested for
quantitative CT (qCT) and histological evaluation. On
day 42, five rats from each group were killed for the qCT
and histological evaluation. The remaining 28 rats were
killed for biomechanical testing.
Callus development analysis via qCT – mineral content
and callus volume. A quantitative determination of callus

development at days 14 and 42 was obtained with a qCT
(XCT 3000, Stratec, Pforzheim, Germany). This method
was selected because it allows 3D, quantitative evaluation of fracture healing, including callus development at
vol. 6, No. 2, February 2017
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the fracture site. Parameters were quantified as the crosssectional transverse area, bone mineral content and
bone density.
After removal of the IM nail, a bony section 3 mm in
length, that included the osteotomy site in the centre,
was analysed using three consecutive transverse qCT
scans of 1.1 mm in thickness and 0.1 mm × 0.1 mm in
pixel size. A total of three images were obtained; one for
the bone fragment proximal to the osteotomy, one for
the osteotomy site itself and one for the distal bone fragment. XCT Series software package (version 5.21, Stratec)
was used to calculate the mineral content, mineralised
callus area and bone mineral density of each image. Total
mineral content and callus volume of the 3 mm segment
was calculated by combining all three section values. In
order to assess progression of remodeling, higher density
callus (> 500 mg/cm3) was measured and separated from
total callus (> 299 mg/cm3). Mineral density greater than
850 mg/cm3 was considered cortical bone density and
was eliminated from newly formed callus calculations.22
Biomechanical evaluation. After euthanasia at day 42,
each femur was harvested and both ends of the femur
were embedded in blocks of polymethylmethacrylate
after removal of the IM nail. Only a 12 mm long segment of the bone, which included the osteotomy in the
centre, was exposed. The specimen was then secured
onto a torsional testing apparatus mounted into an MTS
bi-axial load frame (MTS mini-bionix 858, Minneapolis,
Minnesota). Torsion to failure was applied at a rate of
12°/min.23 There were two parameters derived from the
torque-displacement curve for each specimen’s load
to failure test: torsional stiffness and maximum torque.
Additionally, using the failure pattern, each specimen was
classified into one of four biomechanical stages of fracture repair as described by White et al.24 A Stage I fracture
is rubbery, indicating only soft callus formation. Stages
II through IV exhibit higher stiffness, indicating failure of
bone with progressively higher mineralised tissue. Stage
I and II fractures fail through the original osteotomy line.
Stage III failure occurred partially through the original
osteotomy line and partially through intact bone, while
Stage IV failure occurred entirely through intact bone.
Immunohistochemical expression of iNOS. After fixation in 4% p-formaldehyde, femurs from both days
14 and 42 were decalcified in 10% formic acid for five
days. Each femur was rinsed in PBS, both epiphyses
were removed and the shaft was cut longitudinally in
two halves. Both halves were processed for paraffin
embedding sections. Five-micrometer paraffin embedded sections were employed for immunostaining with
polyclonal antibody (dilution 1:250) against iNOS (BD
Pharmingen, San Diego, California). Next, the sections
were then incubated with biotinylated anti-Rabbit
IgG, respectively, followed by ABC complex (Vector
labs, Temecula, California) and 3,3’diaminobenzidine
(Sigma Aldrich) slides were counter-stained with a
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Table I. Newly formed total and hard callus at the osteotomy site at days 14 and 42 (presented as mean and standard error of the mean)

Group
Newly formed total callus (> 299
Control
Tadalafil
COMB-4
Newly formed hard callus (> 500 mg/cm3)
Control
Tadalafil
COMB-4

Callus volume (mm3)

Mineral content (mg)

Bone density (mg/cm3)

Day 14

Day 42

Day 14

Day 42

Day 14

Day 42

44.0 (4.5)
44.9 (5.8)
37.3 (3.9)

64.0 (9.0)
66.3 (10.1)
63.2 (4.8)

19.7 (2.4)
20.8 (3.2)
16.4 (1.9)

33.0 (5.1)
34.1 (5.7)
31.7 (2.8)

445.8 (11.6)
458.4 (14.6)
438.4 (4.5)

512.2 (8.1)
510.0 (8.5)
500.0 (8.9)

15.1 (2.2)
16.4 (2.4)
13.3 (1.4)

35.7 (5.5)
35.6 (5.6)
33.4 (3.5)

10.0 (1.4)
11.0 (1.6)
8.8 (0.9)

24.6 (3.6)
24.1 (3.7)
22.8 (2.4)

659 (4.7)
665 (1.0)
661 (4.4)

693.2 (11.9)
697.2 (5.5)
683.7 (2.5)

mg/cm3)

n = 4 for day 14 control and tadalafil, and day 42 COMB-4 groups; n = 5 for day 14 COMB-4 and day 42 control and tadalafil groups
COMB-4: L-citrulline, Paullinia cupana, ginger and muira puama

Fig. 2
Representative quantitative CT (qCT) images of the three groups at days 14 and 42. These qCT images were taken 1 mm below the osteotomy site to eliminate
bone fragment overlap at the osteotomy level. The right side bar indicates bone mineral density.

hematoxylin solution. Stained sections were dehydrated
and then mounted with Permount. At least six pictures
per section were taken with a Leica microscope (Leica
Microsystems, Wetzlar, Germany) at 200× magnification. Integrated optical density (IOD) per cell was determined using Image Pro 7.1 software (Media Cybernetics,
Silver Spring, Maryland). After images were calibrated
for background lighting, IOD results are proportional
to the unweighted average optical density, which is
used to determine the concentration of immunoreactive antigen. Each slide assayed had its corresponding
negative control. In all cases, six non-overlapping fields

were screened per tissue sections and at least three
sections per animal were analysed.
Statistical analysis. A one-way analysis of variance
(ANOVA) was used to compare the outcome variables,
including callus volume, bone mineral content, bone
density, torsional stiffness and maximum torque at failure. The independent variables were days 14 and 42 and
treatment type (three categories including control). Oneway ANOVA was followed by least significant difference
post hoc tests to compare individual pairs of groups. Nonparametric tests were used to compare the fracture repair
stages among the three groups.
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Table II. Biomechanical properties of healed fractures at day 42 (from torsion test, presented as mean and standard error of the mean)
Group

Fracture repair stage (I, II, III or IV)†

Maximum torque (Nmm)

Torsional stiffness (Nmm/°)

Control (n = 7)
Tadalafil (n = 10)
COMB-4 (n = 9)

2.4 (0.2) II n = 4; III n = 3; IV n = 0
2.4 (0.2) II n = 6; III n = 4; IV n = 0
2.8 (0.3) II n = 3; III n = 2; IV n = 4

283.3 (59.8)
326.8 (50.0)
421.3 (52.0)* p = 0.029

46.8 (12.8)
59.9 (10.7)
89.9 (11.24)* p = 0.023

*compared with control using analysis of variance followed by least significant difference for multiple comparisons
†fracture repair stage numerical conversion for mean and standard error of the mean
COMB-4: L-citrulline, Paullinia cupana, ginger and muira puama

*

500

25
100

80

300

60

200

40

100

20

Control

Tadalafil

COMB-4

20
Day 14

Day 42

15
*
10

5

0

Fig. 3
Maximum torque (strength) and stiffness of healing fracture at day 42. Results
are expressed as mean and standard error of the mean (* p < 0.05 when compared with control group using analysis of variance followed by least significant difference for multiple comparisons).

For quantitative image analysis of the histological
observations, values were expressed as the mean and
standard error of the mean (sem). The normality distribution of the data was established using the Wilk-Shapiro
test. Multiple comparisons were analysed by a single
factor analysis of variance, followed by post hoc
comparisons with the Tukey test according to GraphPad
Prism (version 5.1) for Windows (GraphPad Software,
San Diego, California). A p-value of < 0.05 was considered significant.

Results

A total of five rats (two from day 14 and three from day
42) were excluded from the study due to either an infection discovered at the osteotomy site (n = 4) or a comminuted fracture (n = 1). Therefore, only 53 animals were
used for the analysis.
Callus development analysis – mineral content and callus
volume. All three groups demonstrated about a 50%

increase in both the mineral content and mineralised
callus volume at the osteotomy site at day 42 when
compared with day 14 (Table I). However, at both of
these time points neither the tadalafil nor the COMB-4
group demonstrated a statistically significant difference compared with the control group. Representative

vol. 6, No. 2, February 2017

iNOS expression (IOD/cell)

400

0

**

Stiffness
Stiffness (Nmm/deg.)

Max. Torque (Nmm)

Torque

*

0

Control

Tadalafil

COMB-4

Fig. 4
Graph showing the effect of tadalafl and COMB-4 on inducible nitric oxide
synthase (iNOS) expression at day 14 and day 42 after femoral osteotomy. The
graph shows quatitative image analysis results of the intensity of iNOS expression per cell. Results are expressed as mean and standard error of the mean
(* p = 0.043; ** p = 0.002 when compared with control group, using analysis
of variance followed by Tukey as post hoc test) (COMB-4: L-citrulline, Paullinia
cupana, ginger and muira puama).

qCT images of the three experimental groups at the
two different time points are shown in Figure 2.
Biomechanical properties. At day 42, the mean values for all three biomechanical parameters (maximum
torque, torsional stiffness and fracture repair stage)
were highest in the COMB-4 group (Table II, Fig. 3).
The COMB-4 group exhibited 46% higher maximum
strength (p = 0.029) and 92% higher stiffness (p = 0.023)
than those of the control group. The COMB-4 group also
exhibited 29% higher maximum strength (p = 0.497) and
50% higher stiffness (p = 0.396) than that of the tadalfil
group but this difference was not statistically significant.
The tadalafil group exhibited 15% higher maximum
strength (p = 0.125) and 28% higher stiffness (p = 0.076)
with respect to the control group, but this change was
not statistically significant.
All of the osteotomies were healed at day 42 and
were higher than Stage II of the biomechanical classification of fracture repair. Stage IV fracture repairs were not
seen in the tadalafil or in the control groups, but were
seen in four rats from the COMB-4 treatment group.
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Fig. 5a

Fig. 5b

Fig. 5c

Fig. 5d

Fig. 5e

Fig. 5f

effect of tadalafil and coMb-4 on inducible nitric oxide synthase (iNoS) expression at day 14 and day 42 after femoral osteotomy determined by immunohistochemistry. Microphotographs of iNoS expression taken at the osteotomy site: a) and b) are control; c) and d) are tadalafil; e) and f) are coMb-4. Panels (a), (c)
and (e) depict 14-day results and panels (b), (d) and (f) depict 42-day results.

The remaining factures in the three groups were either
Stage II or Stage III (Table II).
Immunohistochemical expression of iNOS. at 14 days after
the osteotomy, iNoS expression measured at the callus
level was significantly increased in the tadalafil group
by 30% (9.45 sem 1.08, p = 0.043) and in the coMb-4
group by 180% (18.43 sem 4.34, p = 0.002) when compared with the control group (6.38 sem 1.06) (Fig. 4).
expression of iNoS was localised mostly in chondrocytes
at the level of the cartilaginous callus and in osteoblasts
at the calcification front (Figs 5a, 5c and 5f). however, as
expected, iNoS expression in all three groups at day 42
had returned to baseline values (Figs 5b, 5d and 5f).

Discussion

This study was conceived to determine whether prolonged upregulation of the No-cgMP pathway via iNoS
immediately following a fracture would enhance the
healing process. This hypothesis came about from the
observation that No is involved in fracture healing as
shown by the induction of all three isoforms of NoS in a
specific sequential manner during the fracture healing
process;8-10,25 iNoS is known to be expressed in different
tissues in response to an injury26,27 and its induction in
such injured tissues is considered a protective mechanism against abnormal wound healing;28 iNoS is the first
NoS isoform induced immediately and rapidly following
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a fracture but then tapers off after peaking around the
one- to two-week mark;8-10 and iNOS is closely involved
with osteoblast function and bone formation.11,29
Furthermore, although inhibition of all three NOS genes
will result in retardation of both bone formation and normal fracture healing,9,30 it has been shown that the specific targeted inhibition or deletion of the iNOS enzyme
will negatively impact the fracture healing process while
replacement of the deficient iNOS gene to iNOS deficient
animals will result in normal fracture healing.13
PDE inhibitors are compounds that can upregulate
iNOS via the NO-cGMP pathway31 and have been
reported to enhance fracture healing17 as well as promote the differentiation of osteogenic precursor cells to
osteoblasts.32 However, after 42 days of daily tadalafil,
fracture healing, as measured by either the biomechanical fracture repair stage, maximum torque or torsional
stiffness, was not significantly enhanced when compared
with the control condition.
In contrast, COMB-4, a product consisting of a predetermined mixture of the four natural constituents of
L-citrulline, ginger, muira puama and Paullinia cupana,
recently reported as an up-regulator of iNOS,19 significantly
enhanced fracture healing as measured by biomechanical
properties. In the present study, the smaller mineralised
callus volume and the newly mineralised callus seen in
these COMB-4 animals may be indicative of an accelerated
mineralisation of bridging callus that contributes to the
superior biomechanical properties of the COMB-4 group
compared with both the tadalafil and control groups.
It is possible that the biomechanical findings of the
tadalafil group could be attributed to the dosage of tadalafil used. The 2 mg/kg daily dosage of tadalafil used in
this study was lower than the 5 mg/kg dose reported
in the literature to be efficacious as an anti-fibrotic agent
in the rat.33 This 5 mg/kg dose in the rat is equivalent to
40 mg per day in a human,21 which supersedes the highest human recommended daily dose for this drug when
administered for urological dysfunctions,34 but is considered to be an optimum dose for patients with pulmonary
arterial hypertension.35 We speculate that the difference
in effect between tadalafil and COMB-4 could be attributed to the varying dosages of tadalafil used in the abovementioned studies as well as to absorption of the tadalafil.
Some of those studies used non-soluble media with
ingestion of the product while others used a dissolvable
solution with a differential effect of the product on stimulating iNOS.
Our study in the rat has several limitations. First, we
used an unlocked IM nailing system and, as such, axial
and rotational stability was not fully controlled. This may
have led to some displacement of a fracture fragment
due to a larger medullary canal at the distal diaphysis,
where most of the osteotomies were located, such that
the reduction may not have been perfect and resulted in
different patterns of callus formation.22,36 It is also known
vol. 6, No. 2, February 2017
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that fracture callus development and size are affected by
the stability of the fracture.37 Finally, as stated earlier, the
dosages of tadalafil and COMB-4 were individually calculated based on previous published studies in the rat and
prescribed human dosages. It is possible that these doses
were not optimum for treating a fracture in this animal
model because of potential pharmacokinetic differences
between the human and the rat. Further investigation
using different doses of both tadalafil and COMB-4, singly or in combination, may be required to elucidate the
optimum dose of each product.
This study demonstrates the efficacy of a natural product in enhancing the functional strength of bone following an osteotomy in a rat. COMB-4 by itself resulted in
excellent biomechanical properties associated with fracture healing when compared with that seen with either
the control or tadalafil group. L-citrulline, muira puama,
Paullinia cupana and ginger, the constituents of COMB4, are known in humans to have an innocuous side effect
profile.38,39 It is possible that COMB-4 may play a potential future role in enhancing the healing process associated with musculoskeletal fractures, although additional
studies will certainly be required in humans to confirm its
clinical efficacy.
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